141 related articles for article (PubMed ID: 18971787)
1. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Triozzi PL; Aldrich W; Dombos C
Melanoma Res; 2008 Dec; 18(6):420-30. PubMed ID: 18971787
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma.
Fernandes BF; Di Cesare S; Neto Belfort R; Maloney S; Martins C; Castiglione E; Isenberg J; Abourbih D; Antecka E; Burnier MN
Anal Cell Pathol (Amst); 2011; 34(3):123-30. PubMed ID: 21606571
[TBL] [Abstract][Full Text] [Related]
5. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2337-42. PubMed ID: 18515579
[TBL] [Abstract][Full Text] [Related]
6. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
[TBL] [Abstract][Full Text] [Related]
8. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():35-41. PubMed ID: 19032680
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
10. An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells.
Kirk MJ; Fotiadis NA; Majumdar SK
J Chemother; 2006 Feb; 18(1):49-55. PubMed ID: 16572894
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
13. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
[TBL] [Abstract][Full Text] [Related]
15. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?
All-Ericsson C; Girnita L; Müller-Brunotte A; Brodin B; Seregard S; Ostman A; Larsson O
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2075-82. PubMed ID: 15223779
[TBL] [Abstract][Full Text] [Related]
16. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Samoszuk M; Corwin MA
Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in cutaneous melanoma.
Redondo P; Lloret P; Andreu EJ; Inoges S
J Invest Dermatol; 2004 Dec; 123(6):1208-9. PubMed ID: 15610538
[No Abstract] [Full Text] [Related]
19. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
20. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]